Compare Tango Therapeutics Inc. (TNGX) vs Virtu Financial Inc. Class A Common Stock (VIRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Virtu Financial Inc. Class A Common Stock — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Virtu Financial Inc. Class A Common Stock trades at $55.56 (market cap $4.94B). The key difference: Virtu Financial Inc. Class A Common Stock is the larger of the two by market cap, and Virtu Financial Inc. Class A Common Stock pays a 1.72% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Virtu Financial Inc. Class A Common Stock for 6 Days on average.
| TNGX | VIRT | |
|---|---|---|
Market Cap | $3.75B | $4.94B |
Volume | 9,619,106 | 1,546,091 |
Sector | Health | Financials |
52-Week High | $32.90 | $67.93 |
52-Week Low | $7.50 | $32.53 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.77B | $14.65B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VIRT trades at $55.94, down 1.46% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 9.29, net income margin of 13.5%, and ROE of 31.65%. Recent expansion into Saudi Exchange block trading and consistent earnings outperformance support growth prospects. Analyst consensus price target is $63.00 with mixed ratings (38% buy, 46% hold).
VIRT presents a value opportunity with attractive valuation metrics and strong profitability, though technical indicators suggest near-term pressure. The company's market-making business demonstrates resilience with improving cash flow trends. Key risks include market volatility sensitivity and competitive pressures in financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Virtu Financial Inc. Class A Common Stock
Virtu Financial provides technology-enabled market-making and execution services. Its platforms help institutional, retail, and other market participants trade across global financial markets.
Read more on VIRT →
